| Year |
Citation |
Score |
| 2020 |
Lui GYL, Shaw R, Schaub FX, Stork IN, Gurley KE, Bridgwater C, Diaz RL, Rosati R, Swan HA, Ince TA, Harding TC, Gadi VK, Goff BA, Kemp CJ, Swisher EM, et al. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. Ebiomedicine. 60: 102988. PMID 32927276 DOI: 10.1016/J.Ebiom.2020.102988 |
0.314 |
|
| 2020 |
Zhang J, Kim S, Li L, Kemp CJ, Jiang C, Lü J. Proteomic and transcriptomic profiling of Pten gene-knockout mouse model of prostate cancer. The Prostate. PMID 32162714 DOI: 10.1002/Pros.23972 |
0.311 |
|
| 2020 |
Margossian A, Schaub FX, Richardson A, Churchill M, Rosati R, Dullea A, Whitney GA, Swan H, Diaz R, Appleyard L, Gadi V, Zarrinpar A, Javle M, Kemp C, Pereira S, et al. Abstract 818: Organoid based functional test to predict personalized treatment in cholangiocarcinoma Cancer Research. 80: 818-818. DOI: 10.1158/1538-7445.Am2020-818 |
0.321 |
|
| 2019 |
Shigeta S, Shaw R, Moser R, Gurley K, Lui G, Grandori C, Kemp C. Abstract NT-108: TARGETING BROMODOMAIN PROTEINS AS A THERAPEUTIC STRATEGY FOR CLEAR CELL CARCINOMA OF THE OVARY Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Nt-108 |
0.404 |
|
| 2018 |
Ishibashi M, Toyoshima M, Zhang X, Hasegawa-Minato J, Shigeta S, Usui T, Kemp CJ, Grandori C, Kitatani K, Yaegashi N. Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer. Scientific Reports. 8: 13207. PMID 30181600 DOI: 10.1038/S41598-018-31069-2 |
0.364 |
|
| 2018 |
Grandori C, Kemp CJ. Personalized Cancer Models for Target Discovery and Precision Medicine. Trends in Cancer. 4: 634-642. PMID 30149881 DOI: 10.1016/J.Trecan.2018.07.005 |
0.413 |
|
| 2018 |
Lui GYL, Grandori C, Kemp CJ. CDK12: an emerging therapeutic target for cancer. Journal of Clinical Pathology. PMID 30104286 DOI: 10.1136/Jclinpath-2018-205356 |
0.343 |
|
| 2018 |
Kemp CJ. Eduardo "Eddie" Méndez: In Memoriam (1972-2018). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 24: 2975-2976. PMID 29907678 DOI: 10.1158/1078-0432.Ccr-18-1349 |
0.301 |
|
| 2018 |
Xu C, Nikolova O, Basom R, Mitchell RM, Shaw R, Moser R, Park H, Gurley KE, Kao M, Green CL, Schaub FX, Diaz RL, Swan HA, Jang IS, Guinney J, ... ... Kemp CJ, et al. Functional precision medicine identifies novel druggable targets and therapeutic options in head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29599409 DOI: 10.1158/1078-0432.Ccr-17-1339 |
0.337 |
|
| 2018 |
Churchill MJ, Schaub FX, Swan HA, Rosati R, Yan F, Shaw RC, Gurley KE, Diaz RL, Pereira SC, Grandori C, Kemp CJ, Gadi VK. Abstract 1603: Patient derived tumor organoids identify actionable targets in heavily pretreated metastatic breast cancer patients Cancer Research. 78: 1603-1603. DOI: 10.1158/1538-7445.Am2018-1603 |
0.387 |
|
| 2017 |
Nguyen HH, Tilton SC, Kemp CJ, Song M. Nonmonotonic Pathway Gene Expression Analysis Reveals Oncogenic Role of p27/Kip1 at Intermediate Dose. Cancer Informatics. 16: 1176935117740132. PMID 29162974 DOI: 10.1177/1176935117740132 |
0.416 |
|
| 2017 |
Gurley KE, Ashley AK, Moser RD, Kemp CJ. Synergy between Prkdc and Trp53 regulates stem cell proliferation and GI-ARS after irradiation. Cell Death and Differentiation. PMID 28686579 DOI: 10.1038/Cdd.2017.107 |
0.402 |
|
| 2017 |
Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R, McNary TJ, Churakova Y, Cheung C, Triscott J, Pisapia D, ... ... Kemp CJ, et al. Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer Discovery. PMID 28331002 DOI: 10.1158/2159-8290.Cd-16-1154 |
0.373 |
|
| 2017 |
Nikolova O, Moser R, Kemp C, Onen MG, Margolin AA. Modeling Gene-Wise Dependencies Improves the Identification of Drug Response Biomarkers in Cancer Studies. Bioinformatics (Oxford, England). PMID 28082455 DOI: 10.1093/Bioinformatics/Btw836 |
0.31 |
|
| 2017 |
Lui GYL, Schaub F, Agrawal S, Kitatani K, Kemp CJ, Toyoshima M, Grandori C. Abstract A28: Casein kinase 1ϵ (CSNK1ϵ) is a synthetic lethal target in MYC-driven ovarian cancer Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-A28 |
0.414 |
|
| 2017 |
Zhang J, Li L, Kim S, Higgins L, Deng Y, Kemp CJ, Jiang C, Lu J. Abstract 5249: Integrative analysis of transcriptomic, proteomic, and metabolomic data ofPten-knockout carcinogenic mouse prostate Cancer Research. 77: 5249-5249. DOI: 10.1158/1538-7445.Am2017-5249 |
0.325 |
|
| 2015 |
Kemp CJ. Animal Models of Chemical Carcinogenesis: Driving Breakthroughs in Cancer Research for 100 Years. Cold Spring Harbor Protocols. 2015: pdb.top069906. PMID 26430259 DOI: 10.1101/Pdb.Top069906 |
0.361 |
|
| 2015 |
Gurley KE, Moser RD, Kemp CJ. Induction of Liver Tumors in Mice with N-Ethyl-N-Nitrosourea or N-Nitrosodiethylamine. Cold Spring Harbor Protocols. 2015: pdb.prot077438. PMID 26430250 DOI: 10.1101/Pdb.Prot077438 |
0.387 |
|
| 2015 |
Gurley KE, Moser RD, Kemp CJ. Induction of Colon Cancer in Mice with 1,2-Dimethylhydrazine. Cold Spring Harbor Protocols. 2015: pdb.prot077453. PMID 26330619 DOI: 10.1101/Pdb.Prot077453 |
0.45 |
|
| 2015 |
Gurley KE, Moser RD, Kemp CJ. Induction of Lung Tumors in Mice with Urethane. Cold Spring Harbor Protocols. 2015: pdb.prot077446. PMID 26330618 DOI: 10.1101/Pdb.Prot077446 |
0.434 |
|
| 2015 |
Yang F, Kemp CJ, Henikoffa S. Anthracyclines induce double-strand DNA breaks at active gene promoters. Mutation Research. 773: 9-15. PMID 25705119 DOI: 10.1016/J.Mrfmmm.2015.01.007 |
0.343 |
|
| 2015 |
Mishra R, Watanabe T, Kimura MT, Koshikawa N, Ikeda M, Uekusa S, Kawashima H, Wang X, Igarashi J, Choudhury D, Grandori C, Kemp CJ, Ohira M, Verma NK, Kobayashi Y, et al. Identification of a novel E-box binding pyrrole-imidazole polyamide inhibiting MYC-driven cell proliferation. Cancer Science. 106: 421-9. PMID 25611295 DOI: 10.1111/Cas.12610 |
0.361 |
|
| 2015 |
Westcott PM, Halliwill KD, To MD, Rashid M, Rust AG, Keane TM, Delrosario R, Jen KY, Gurley KE, Kemp CJ, Fredlund E, Quigley DA, Adams DJ, Balmain A. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature. 517: 489-92. PMID 25363767 DOI: 10.1038/Nature13898 |
0.365 |
|
| 2014 |
Moser R, Xu C, Kao M, Annis J, Lerma LA, Schaupp CM, Gurley KE, Jang IS, Biktasova A, Yarbrough WG, Margolin AA, Grandori C, Kemp CJ, Méndez E. Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4274-88. PMID 25125259 DOI: 10.1158/1078-0432.Ccr-13-2858 |
0.315 |
|
| 2014 |
Kemp CJ, Moore JM, Moser R, Bernard B, Teater M, Smith LE, Rabaia NA, Gurley KE, Guinney J, Busch SE, Shaknovich R, Lobanenkov VV, Liggitt D, Shmulevich I, Melnick A, et al. CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer. Cell Reports. 7: 1020-9. PMID 24794443 DOI: 10.1016/J.Celrep.2014.04.004 |
0.723 |
|
| 2014 |
Yang F, Teves SS, Kemp CJ, Henikoff S. Doxorubicin, DNA torsion, and chromatin dynamics. Biochimica Et Biophysica Acta. 1845: 84-9. PMID 24361676 DOI: 10.1016/J.Bbcan.2013.12.002 |
0.382 |
|
| 2014 |
Busch SE, Moser RD, Gurley KE, Kelly-Spratt KS, Liggitt HD, Kemp CJ. ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma. Oncogene. 33: 2665-73. PMID 23752194 DOI: 10.1038/Onc.2013.208 |
0.729 |
|
| 2014 |
Nikolova OH, Gönen M, Dienstmann R, Jang IS, Moser R, Cermelli S, Xu C, Mitchell RM, Mendez E, Grandori C, Kemp C, Friend S, Guinney J, Margolin A. Abstract 5323: Integrated computational cell-line modeling of drug sensitivity and high-throughput siRNA screening reveals novel molecular biomarkers for conventional chemotherapy Cancer Research. 74: 5323-5323. DOI: 10.1158/1538-7445.Am2014-5323 |
0.323 |
|
| 2013 |
Diede SJ, Yao Z, Keyes CC, Tyler AE, Dey J, Hackett CS, Elsaesser K, Kemp CJ, Neiman PE, Weiss WA, Olson JM, Tapscott SJ. Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer. Epigenetics : Official Journal of the Dna Methylation Society. 8: 1254-60. PMID 24107773 DOI: 10.4161/Epi.26486 |
0.378 |
|
| 2013 |
Yang F, Kemp CJ, Henikoff S. Doxorubicin enhances nucleosome turnover around promoters. Current Biology : Cb. 23: 782-7. PMID 23602475 DOI: 10.1016/J.Cub.2013.03.043 |
0.381 |
|
| 2013 |
Yang F, Kemp CJ, Henikoff S. Abstract PR11: Doxorubicin enhances nucleosome turnover around active gene promoters Cancer Research. 73. DOI: 10.1158/1538-7445.Cec13-Pr11 |
0.399 |
|
| 2012 |
Busch SE, Gurley KE, Moser RD, Kemp CJ. ARF suppresses hepatic vascular neoplasia in a carcinogen-exposed murine model. The Journal of Pathology. 227: 298-305. PMID 22430984 DOI: 10.1002/Path.4024 |
0.677 |
|
| 2012 |
Moser R, Toyoshima M, Robinson K, Gurley KE, Howie HL, Davison J, Morgan M, Kemp CJ, Grandori C. MYC-driven tumorigenesis is inhibited by WRN syndrome gene deficiency. Molecular Cancer Research : McR. 10: 535-45. PMID 22301954 DOI: 10.1158/1541-7786.Mcr-11-0508 |
0.481 |
|
| 2012 |
Moore JM, Moser R, Smith L, Gurley K, Liggett D, Filippova G, Kemp CJ. Abstract 118: CTCF, a master epigenetic regulator, is a haploinsufficient tumor suppressor gene in multiple cell lineages Cancer Research. 72: 118-118. DOI: 10.1158/1538-7445.Am2012-118 |
0.474 |
|
| 2011 |
Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faça VM, Kelly-Spratt K, Wong CH, Zhang Q, Chin A, Park KS, Goodman G, Gazdar AF, Sage J, Dinulescu DM, Kucherlapati R, ... ... Kemp CJ, et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell. 20: 289-99. PMID 21907921 DOI: 10.1016/J.Ccr.2011.08.007 |
0.39 |
|
| 2011 |
Whiteaker JR, Lin C, Kennedy J, Hou L, Trute M, Sokal I, Yan P, Schoenherr RM, Zhao L, Voytovich UJ, Kelly-Spratt KS, Krasnoselsky A, Gafken PR, Hogan JM, Jones LA, ... ... Kemp CJ, et al. A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nature Biotechnology. 29: 625-34. PMID 21685906 DOI: 10.1038/Nbt.1900 |
0.305 |
|
| 2011 |
Pitteri SJ, Kelly-Spratt KS, Gurley KE, Kennedy J, Buson TB, Chin A, Wang H, Zhang Q, Wong CH, Chodosh LA, Nelson PS, Hanash SM, Kemp CJ. Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. Cancer Research. 71: 5090-100. PMID 21653680 DOI: 10.1158/0008-5472.Can-11-0568 |
0.423 |
|
| 2011 |
Kelly-Spratt KS, Pitteri SJ, Gurley KE, Liggitt D, Chin A, Kennedy J, Wong CH, Zhang Q, Buson TB, Wang H, Hanash SM, Kemp CJ. Plasma proteome profiles associated with inflammation, angiogenesis, and cancer. Plos One. 6: e19721. PMID 21589862 DOI: 10.1371/Journal.Pone.0019721 |
0.39 |
|
| 2011 |
Schoenherr RM, Kelly-Spratt KS, Lin C, Whiteaker JR, Liu T, Holzman T, Coleman I, Feng LC, Lorentzen TD, Krasnoselsky AL, Wang P, Liu Y, Gurley KE, Amon LM, Schepmoes AA, ... ... Kemp CJ, et al. Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer. Proteomics. Clinical Applications. 5: 179-88. PMID 21448875 DOI: 10.1002/Prca.201000037 |
0.325 |
|
| 2011 |
Busch SE, Gurley KE, Moser RD, Kelly-Spratt KS, Kemp CJ. Abstract A34: Arf suppresses the growth and progression of Kras-driven lung tumors Cancer Research. 71. DOI: 10.1158/1538-7445.Fbcr11-A34 |
0.722 |
|
| 2011 |
Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faça VM, Sage J, Kemp CJ, Varmus HE, Hanash SM. Abstract 3166: Lung cancer bio-signatures in plasma based on the analysis of mouse models Cancer Research. 71: 3166-3166. DOI: 10.1158/1538-7445.Am2011-3166 |
0.395 |
|
| 2009 |
Kelly-Spratt KS, Philipp-Staheli J, Gurley KE, Hoon-Kim K, Knoblaugh S, Kemp CJ. Inhibition of PI-3K restores nuclear p27Kip1 expression in a mouse model of Kras-driven lung cancer. Oncogene. 28: 3652-62. PMID 19648963 DOI: 10.1038/Onc.2009.226 |
0.463 |
|
| 2009 |
Glover CE, Gurley KE, Kim KH, Storer B, Fero ML, Kemp CJ. Endocrine dysfunction in p27Kip1 deficient mice and susceptibility to Wnt-1 driven breast cancer. Carcinogenesis. 30: 1058-63. PMID 19380520 DOI: 10.1093/Carcin/Bgp089 |
0.404 |
|
| 2009 |
Gurley KE, Moser R, Gu Y, Hasty P, Kemp CJ. DNA-PK suppresses a p53-independent apoptotic response to DNA damage. Embo Reports. 10: 87-93. PMID 19057578 DOI: 10.1038/Embor.2008.214 |
0.365 |
|
| 2008 |
Tian Y, Kelly-Spratt KS, Kemp CJ, Zhang H. Identification of glycoproteins from mouse skin tumors and plasma. Clinical Proteomics. 4: 117-136. PMID 21072318 DOI: 10.1007/S12014-008-9014-Z |
0.406 |
|
| 2008 |
Letarte S, Brusniak MY, Campbell D, Eddes J, Kemp CJ, Lau H, Mueller L, Schmidt A, Shannon P, Kelly-Spratt KS, Vitek O, Zhang H, Aebersold R, Watts JD. Differential Plasma Glycoproteome of p19 Skin Cancer Mouse Model Using the Corra Label-Free LC-MS Proteomics Platform. Clinical Proteomics. 4: 105. PMID 20157627 DOI: 10.1007/S12014-008-9018-8 |
0.347 |
|
| 2008 |
Grosse-Wilde A, Kemp CJ. Metastasis suppressor function of tumor necrosis factor-related apoptosis-inducing ligand-R in mice: implications for TRAIL-based therapy in humans? Cancer Research. 68: 6035-7. PMID 18676822 DOI: 10.1158/0008-5472.Can-08-0078 |
0.416 |
|
| 2008 |
Kelly-Spratt KS, Kasarda AE, Igra M, Kemp CJ. A mouse model repository for cancer biomarker discovery. Journal of Proteome Research. 7: 3613-8. PMID 18624399 DOI: 10.1021/Pr800210B |
0.379 |
|
| 2008 |
Bailey SL, Gurley KE, Hoon-Kim K, Kelly-Spratt KS, Kemp CJ. Tumor suppression by p53 in the absence of Atm. Molecular Cancer Research : McR. 6: 1185-92. PMID 18583527 DOI: 10.1158/1541-7786.Mcr-07-2009 |
0.45 |
|
| 2008 |
Pitteri SJ, Faca VM, Kelly-Spratt KS, Kasarda AE, Wang H, Zhang Q, Newcomb L, Krasnoselsky A, Paczesny S, Choi G, Fitzgibbon M, McIntosh MW, Kemp CJ, Hanash SM. Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. Journal of Proteome Research. 7: 1481-9. PMID 18311905 DOI: 10.1021/Pr7007994 |
0.352 |
|
| 2008 |
Ruddell A, Kelly-Spratt KS, Furuya M, Parghi SS, Kemp CJ. p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis. Oncogene. 27: 3145-55. PMID 18059331 DOI: 10.1038/Sj.Onc.1210973 |
0.359 |
|
| 2008 |
Payne SR, Zhang S, Tsuchiya K, Moser R, Gurley KE, Longton G, deBoer J, Kemp CJ. p27kip1 deficiency impairs G2/M arrest in response to DNA damage, leading to an increase in genetic instability. Molecular and Cellular Biology. 28: 258-68. PMID 17954563 DOI: 10.1128/Mcb.01536-07 |
0.457 |
|
| 2007 |
Gurley KE, Kemp CJ. Ataxia-telangiectasia mutated is not required for p53 induction and apoptosis in irradiated epithelial tissues. Molecular Cancer Research : McR. 5: 1312-8. PMID 18171989 DOI: 10.1158/1541-7786.Mcr-07-0223 |
0.387 |
|
| 2007 |
Whiteaker JR, Zhang H, Zhao L, Wang P, Kelly-Spratt KS, Ivey RG, Piening BD, Feng LC, Kasarda E, Gurley KE, Eng JK, Chodosh LA, Kemp CJ, McIntosh MW, Paulovich AG. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. Journal of Proteome Research. 6: 3962-75. PMID 17711321 DOI: 10.1021/Pr070202V |
0.356 |
|
| 2006 |
Cobb MJ, Chen Y, Bailey SL, Kemp CJ, Li X. Non-invasive imaging of carcinogen-induced early neoplasia using ultrahigh-resolution optical coherence tomography. Cancer Biomarkers : Section a of Disease Markers. 2: 163-73. PMID 17192069 DOI: 10.3233/Cbm-2006-23-408 |
0.36 |
|
| 2006 |
Besson A, Gurian-West M, Chen X, Kelly-Spratt KS, Kemp CJ, Roberts JM. A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes & Development. 20: 47-64. PMID 16391232 DOI: 10.1101/Gad.1384406 |
0.399 |
|
| 2005 |
Payne SR, Kemp CJ. Tumor suppressor genetics. Carcinogenesis. 26: 2031-45. PMID 16150895 DOI: 10.1093/Carcin/Bgi223 |
0.391 |
|
| 2005 |
Kemp CJ. Multistep skin cancer in mice as a model to study the evolution of cancer cells. Seminars in Cancer Biology. 15: 460-73. PMID 16039870 DOI: 10.1016/J.Semcancer.2005.06.003 |
0.461 |
|
| 2005 |
King TJ, Gurley KE, Prunty J, Shin JL, Kemp CJ, Lampe PD. Deficiency in the gap junction protein connexin32 alters p27Kip1 tumor suppression and MAPK activation in a tissue-specific manner. Oncogene. 24: 1718-26. PMID 15608667 DOI: 10.1038/Sj.Onc.1208355 |
0.466 |
|
| 2004 |
Kelly-Spratt KS, Gurley KE, Yasui Y, Kemp CJ. p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. Plos Biology. 2: E242. PMID 15314658 DOI: 10.1371/Journal.Pbio.0020242 |
0.436 |
|
| 2004 |
Philipp-Staheli J, Kim KH, Liggitt D, Gurley KE, Longton G, Kemp CJ. Distinct roles for p53, p27Kip1, and p21Cip1 during tumor development. Oncogene. 23: 905-13. PMID 14647411 DOI: 10.1038/Sj.Onc.1207220 |
0.44 |
|
| 2003 |
Payne SR, Kemp CJ. p27(Kip1) (Cdkn1b)-deficient mice are susceptible to chemical carcinogenesis and may be a useful model for carcinogen screening. Toxicologic Pathology. 31: 355-63. PMID 12851100 DOI: 10.1080/01926230390201273 |
0.337 |
|
| 2002 |
Philipp-Staheli J, Kim KH, Payne SR, Gurley KE, Liggitt D, Longton G, Kemp CJ. Pathway-specific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice. Cancer Cell. 1: 355-68. PMID 12086850 DOI: 10.1016/S1535-6108(02)00054-5 |
0.479 |
|
| 2001 |
Philipp-Staheli J, Payne SR, Kemp CJ. p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Experimental Cell Research. 264: 148-68. PMID 11237531 DOI: 10.1006/Excr.2000.5143 |
0.437 |
|
| 2001 |
Gurley KE, Kemp CJ. Synthetic lethality between mutation in Atm and DNA-PK(cs) during murine embryogenesis. Current Biology : Cb. 11: 191-4. PMID 11231155 DOI: 10.1016/S0960-9822(01)00048-3 |
0.333 |
|
| 1999 |
Kemp CJ, Vo K, Gurley KE. Resistance to skin tumorigenesis in DNAPK-deficient SCID mice is not due to immunodeficiency but results from hypersensitivity to TPA-induced apoptosis. Carcinogenesis. 20: 2051-6. PMID 10545405 DOI: 10.1093/Carcin/20.11.2051 |
0.418 |
|
| 1999 |
Philipp J, Vo K, Gurley KE, Seidel K, Kemp CJ. Tumor suppression by p27Kip1 and p21Cip1 during chemically induced skin carcinogenesis. Oncogene. 18: 4689-98. PMID 10467416 DOI: 10.1038/Sj.Onc.1202840 |
0.448 |
|
| 1999 |
Kemp CJ. Comparative hepatocellular cancer genetics. The American Journal of Pathology. 154: 975-7. PMID 10233833 DOI: 10.1016/S0002-9440(10)65347-3 |
0.446 |
|
| 1998 |
Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature. 396: 177-80. PMID 9823898 DOI: 10.1038/24179 |
0.398 |
|
| 1997 |
Gersten KM, Kemp CJ. Normal meiotic recombination in p53-deficient mice. Nature Genetics. 17: 378-9. PMID 9398833 DOI: 10.1038/Ng1297-378 |
0.357 |
|
| 1996 |
Gurley KE, Kemp CJ. p53 induction, cell cycle checkpoints, and apoptosis in DNAPK-deficient scid mice. Carcinogenesis. 17: 2537-42. PMID 9006086 DOI: 10.1093/Carcin/17.12.2537 |
0.387 |
|
| 1996 |
Cano A, Gamallo C, Kemp CJ, Benito N, Palacios J, Quintanilla M, Balmain A. Expression pattern of the cell adhesion molecules. E-cadherin, P-cadherin and alpha 6 beta 4 intergrin is altered in pre-malignant skin tumors of p53-deficient mice. International Journal of Cancer. Journal International Du Cancer. 65: 254-62. PMID 8567126 DOI: 10.1002/(Sici)1097-0215(19960117)65:2<254::Aid-Ijc21>3.0.Co;2-C |
0.387 |
|
| 1995 |
Kemp CJ. Hepatocarcinogenesis in p53-deficient mice. Molecular Carcinogenesis. 12: 132-6. PMID 7893366 DOI: 10.1002/Mc.2940120304 |
0.393 |
|
| 1995 |
Nagase H, Bryson S, Cordell H, Kemp CJ, Fee F, Balmain A. Distinct genetic loci control development of benign and malignant skin tumours in mice. Nature Genetics. 10: 424-9. PMID 7670492 DOI: 10.1038/Ng0895-424 |
0.333 |
|
| 1994 |
Kemp CJ, Wheldon T, Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nature Genetics. 8: 66-9. PMID 7987394 DOI: 10.1038/Ng0994-66 |
0.373 |
|
| 1994 |
Bremner R, Kemp CJ, Balmain A. Induction of different genetic changes by different classes of chemical carcinogens during progression of mouse skin tumors. Molecular Carcinogenesis. 11: 90-7. PMID 7916997 DOI: 10.1002/Mc.2940110206 |
0.401 |
|
| 1993 |
Kemp CJ, Donehower LA, Bradley A, Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors Cell. 74: 813-822. PMID 8374952 DOI: 10.1016/0092-8674(93)90461-X |
0.463 |
|
| 1993 |
Brown K, Kemp CJ, Burns PA, Stoler AB, Fowlis DJ, Akhurst RJ, Balmain A. Positive and negative growth control in multistage skin carcinogenesis Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer. 128: 309-321. PMID 8356328 DOI: 10.1007/978-3-642-84881-0_23 |
0.301 |
|
| 1993 |
Kemp CJ, Bremner R, Balmain A. A revised map position for the Ha-ras gene on mouse chromosome 7: Implications for analysis of genetic alterations in rodent tumors Molecular Carcinogenesis. 7: 147-150. PMID 8098216 DOI: 10.1002/Mc.2940070304 |
0.316 |
|
| 1990 |
Drinkwater NR, Hanigan MH, Kemp CJ. Genetic determinants of hepatocarcinogenesis in the B6C3F1 mouse. Toxicology Letters. 49: 255-65. PMID 2690405 DOI: 10.1016/0378-4274(89)90036-2 |
0.391 |
|
| 1989 |
Kemp CJ, Leary CN, Drinkwater NR. Promotion of murine hepatocarcinogenesis by testosterone is androgen receptor-dependent but not cell autonomous. Proceedings of the National Academy of Sciences of the United States of America. 86: 7505-9. PMID 2798421 DOI: 10.1073/Pnas.86.19.7505 |
0.377 |
|
| 1988 |
Hanigan MH, Kemp CJ, Ginsler JJ, Drinkwater NR. Rapid growth of preneoplastic lesions in hepatocarcinogen-sensitive C3H/HeJ male mice relative to C57BL/6J male mice. Carcinogenesis. 9: 885-90. PMID 3370754 DOI: 10.1093/Carcin/9.6.885 |
0.332 |
|
| Show low-probability matches. |